Everything below concerns circadian clock. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
The importance of the TGF-β pathway was confirmed with the discovery of the similar Loeys–Dietz syndrome involving the TGFβR2 gene on chromosome 3, a receptor protein of TGF-β. Marfan syndrome has often been confused with Loeys–Dietz syndrome, because of the considerable clinical overlap between the two pathologies.
Many reaction intermediates with variable stability can thus be envisaged during the course of a reaction. Reaction mechanisms are proposed to explain the kinetics and the relative product mix of a reaction. Many physical chemists specialize in exploring and proposing the mechanisms of various chemical reactions. Several empirical rules, like the Woodward–Hoffmann rules often come in handy while proposing a mechanism for a chemical reaction. According to the IUPAC gold book, a chemical reaction is "a process that results in the interconversion of chemical species." Accordingly, a chemical reaction may be an elementary reaction or a stepwise reaction. An additional caveat is made, in that this definition includes cases where the interconversion of conformers is experimentally observable. Such detectable chemical reactions normally involve sets of molecular entities as indicated by this definition, but it is often conceptually convenient to use the term also for changes involving single molecular entities (i.e. 'microscopic chemical events').
==== Astronomy ==== In astronomy, in situ measurement involves collecting data directly at or near a celestial object using spacecraft or instruments physically present at the location. For example, the Parker Solar Probe conducts in situ studies of the Sun's atmosphere, while the Cassini–Huygens mission similarly analyzed Saturn's magnetosphere. In situ formation refers to astronomical objects that formed at their current locations without significant migration. Some theories propose that planets, such as Earth, formed in their present orbits rather than moving from elsewhere. Star clusters may form within their host galaxy, rather than being accreted from external sources.
A broad array of biological specimens, including blood, urine, gastric contents, oral fluids, hair, and tissues, may undergo analysis. Forensic toxicologists collaborate with pathologists, medical examiners, and coroners to ascertain the cause and manner of death. Human Performance toxicology examines the dose-response relationship between drugs present in the body and their effects. This field plays a pivotal role in shaping and implementing laws related to activities such as driving under the influence of alcohol or drugs. Lastly, Forensic Drug Testing (FDT) pertains to detecting drug use in contexts such as the workplace, sport doping, drug-related probation, and screenings for new job applicants. Identifying the ingested substance ingested is frequently challenging due to the body's natural processes (as outlined in ADME). It is uncommon for a chemical to persist in its original form once inside the body. For instance, heroin rapidly undergoes metabolism, ultimately converting to morphine. Consequently, a thorough examination of factors such as injection marks and chemical purity becomes imperative for an accurate diagnosis. Additionally, the substance might undergo dilution as it disperses throughout the body. Unlike a regulated dose of a drug, which may contain grams or milligrams of the active constituent, an individual sample under investigation may only consist of micrograms or nanograms.
=== United States === Prominent outdoor retailers in the United States include Dick's Sporting Goods, Eddie Bauer, Backcountry.com, Outdoor Voices, REI, Patagonia, Marmot, Moosejaw, Sierra, The North Face and L.L.Bean.
Sources: en.wikipedia.org
== Signs and symptoms == Hyperglycemia may be asymptomatic. Blood glucose levels can rise above normal and cause pathological and functional changes for significant periods without producing any permanent effects or symptoms. The degree of hyperglycemia can change over time depending on the metabolic cause, for example, impaired glucose tolerance or fasting glucose, and it can depend on treatment. The following symptoms may be associated with acute or chronic hyperglycemia, with the first three composing the classic hyperglycemic triad:
Metallic zinc was isolated in India by 1300 AD. Before it was isolated in Europe, it was imported from India in about AD 1600. Postlewayt's Universal Dictionary, a contemporary source giving technological information in Europe, did not mention zinc before 1751 but the element was studied before then. Flemish metallurgist and alchemist P. M. de Respour reported that he had extracted metallic zinc from zinc oxide in 1668. By the start of the 18th century, Étienne François Geoffroy described how zinc oxide condenses as yellow crystals on bars of iron placed above zinc ore that is being smelted. In Britain, John Lane is said to have carried out experiments to smelt zinc, probably at Landore, prior to his bankruptcy in 1726. In 1738 in Great Britain, William Champion patented a process to extract zinc from calamine in a vertical retort-style smelter. His technique resembled that used at Zawar zinc mines in Rajasthan, but no evidence suggests he visited the Orient. Champion's process was used through 1851. German chemist Andreas Marggraf normally gets credit for isolating pure metallic zinc in the West, even though Swedish chemist Anton von Swab had distilled zinc from calamine four years previously. In his 1746 experiment, Marggraf heated a mixture of calamine and charcoal in a closed vessel without copper to obtain a metal. This procedure became commercially practical by 1752.
After tracing the adaptation strategy of the party, he found confirming evidence for five of the factors contributing to its electoral success, already mentioned in the theoretical literature on former Marxist–Leninist parties, namely the economic situation, the weakness of the opponents, the electoral laws, the fragmentation of the political spectrum and the legacy of the old regime. However, Marandici identified seven additional explanatory factors at work in the Moldovan case, namely the foreign support for certain political parties, separatism, the appeal to the ethnic minorities, the alliance-building capacity, the reliance on the Soviet notion of the Moldovan identity, the state-building process and the control over a significant portion of the media. It is due to these seven additional factors that the party managed to consolidate and expand its constituency. In the post-Soviet states, the Party of Communists are the only ones who have been in power for so long and did not change the name of the party. In Asia, a number of Marxist–Leninist regimes and movements continue to exist. The People's Republic of China has continued the agenda of Deng Xiaoping's 1980s reforms by initiating significant privatisation of the national economy. At the same time, no corresponding political liberalisation has occurred as happened in previous years to Eastern European countries.
== Culinary use == Shimeji should always be cooked: it is not a good mushroom to serve raw due to a somewhat bitter taste, but the bitterness disappears completely upon cooking. The cooked mushroom has a pleasant, firm, slightly crunchy texture and a slightly nutty flavor. Cooking also makes this mushroom easier to digest. It works well in stir-fried foods like stir-fried vegetables, as well as with wild game or seafood. Also, it can be used in soups, stews, and in sauces. When cooked alone, Shimeji mushrooms can be sautéed whole, including the stem or stalk (only the very end cut off), using a higher temperature or they can be slow roasted at a low temperature with a small amount of butter or cooking oil. Shimeji is used in soups, nabe and takikomi gohan.
The Cold War is increasingly treated as a global historical period beginning customarily in 1947 when the Truman Doctrine sought to contain communism and the expansion of Soviet influence, and ending with the decline and fall of the Soviet Union and the Eastern bloc in the late 1980s.
Sources: en.wikipedia.org
Brendan Lee (born 9 September 1987) is a former professional Australian rules football player at the Essendon Football Club in the Australian Football League (AFL), and most notable for his long career with East Perth in the West Australian Football League (WAFL). Originally from East Perth, Lee made his senior WAFL debut in 2007 at age 19. By 2010, he was a regular senior player for the Royals, and he won the club's best and fairest award in 2011. After sixty games for the club and at age 24, he was recruited to the Australian Football League by Essendon with a late selection in the 2012 Rookie Draft (No. 78 overall). He played two senior games for Essendon during 2012, debuting in Round 20 against North Melbourne at Docklands Stadium, and played in the Victorian Football League for Essendon's VFL-affiliate Bendigo during the season. He was delisted at the end of the season, and returned to East Perth, where he won another club best and fairest in 2013 and became club captain. Lee, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his team-mates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 WAFL season.
==== Release ==== The decision to release Olofsson came after a negotiation on conditional release in Belgium at the end of May 2018. On 30 July 2018, Olofsson landed at Landvetter Airport outside Gothenburg, Sweden as a free man.
=== Roads and highways === As of May 2010, the borough had a total of 37.02 miles (59.58 km) of roadways, of which 33.65 miles (54.15 km) were maintained by the municipality and 3.37 miles (5.42 km) by Bergen County. County Route 505 and County Route 501 travel through Cresskill.
=== Pharmacodynamics === 3-HO-PCP acts as a high-affinity uncompetitive NMDA receptor antagonist via the PCP site with a Ki of 30 nM. It has a higher affinity than PCP, which has a Ki of 250 nM for this site (eight-fold higher). Unlike many other arylcyclohexylamines, including close analogues such as 3-Chloro-PCP and 3-MeO-PCP, 3-HO-PCP has a high affinity for various opioid receptors. It has a Ki value of 39–60 nM for the μ-opioid receptor, 140 nM for the κ-opioid receptor, and 42 nM for the σ1 receptor. It has weaker activity at the δ-opioid receptor, with a Ki of 2,300 nM.
=== Economics === Belimumab is primarily used in people with systemic lupus erythematosus. When it was introduced in 2011, it was the first new drug approved to treat lupus in 56 years. Sales rose to $31.2 million in the first quarter of 2012. The total cost for the first year of treatment with belimumab is $28,000. Belimumab is much more expensive than other drugs used to treat lupus, including prednisone ($140 per year), hydroxychloroquine ($132), oral methotrexate ($432), azathioprine ($468), and mycophenolate mofetil ($1,224). In the United Kingdom, the National Institute for Health and Care Excellence calculated the cost of belimumab at £61,200 per quality-adjusted life year (QALY). This is more than the normally accepted cost of £20,000 to £30,000 per QALY. The manufacturer offered the UK National Health Service a discount of a confidential amount, which still did not bring it into the acceptable range.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.